Ces radiol. 2024, 78(2):101-114 | DOI: 10.55095/CesRadiol2024/014

Standardisation of MRI usage inReview article

Manuela Vaněčková1, Dominika Šťastná2, Pavel Ryška3, Radek Tupý4, Miloš Keřkovský5, Michal Holešta6, Marek Peterka7, 8, Pavel Hradílek9, Jiří Palíšek10, Jana Prokešová11, Marta Vachová2,12, Pavla Hanzlíková13, Martin Kynčl14, Martina Wolhmutová15, Miroslav Heřman16, Leoš Ungermann17, Jana Votrubová18, Marta Pažourková19, Petr Lhoták20, Dana Horáková2, Eva Kubala Havrdová2, Jan Mareš21
1 Oddělení MR, Radiodiagnostická klinika 1. LF UK a VFN, Praha
2 Neurologická klinika a Centrum klinických neurověd 1. LF UK a VFN, Praha
3 Radiologická klinika LF UK a FN, Hradec Králové
4 Klinika zobrazovacích metod LF UK a FN, Plzeň
5 Klinika radiologie a nukleární medicíny LF MU a FN, Brno
6 Klinika radiologie a nukleární medicíny 3. LF UK a FNKV, Praha
7 Neurologická klinika LF UK a FN, Plzeň
8 Neurologická klinika LF UK a FN, Hradec Králové
9 Neurologická klinika LF OU a FN, Ostrava
10 Oddělení zobrazovacích metod KNTB, Zlín
11 Radiodiagnostické oddělení KZN, Teplice
12 Neurologické oddělení KZN, Teplice
13 Radiodiagnostický ústav a ÚZM LF OU a FN, Ostrava
14 Klinika zobrazovacích metod 2. LF UK a FN Motol, Praha
15 Oddělení zobrazovacích metod, Nemocnice Jihlava
16 Radiologická klinika LF UP a FN, Olomouc
17 Radiologické oddělení KN, Pardubice
18 Radiologické oddělení Thomayerovy nemocnice, Praha
19 Klinika zobrazovacích metod Fakultní nemocnice u sv. Anny v Brně
20 Radiodiagnostické oddělení FN, České Budějovice
21 Neurologická klinika LF UP a FN, Olomouc

Magnetic resonance imaging (MRI) plays a key role in managing patients withmultiple sclerosis (MS) - in diagnosis and determining prognostic markers, aswell as in monitoring early signals of treatment ineffectiveness and safetyproblems. However, standardisation across sites is essential to maximise itspotential. Close interdisciplinary communication between radiologists andneurologists and unification of the request form and structured radiologicaldescription are also essential. To this end, for this purpose, with thesupport of the Czech Society of Neuroradiology and the Section of the ClinicalNeuroimmunology and Neurology Section of the Czech Neurological Society, thisconsensus of the Czech expert radiology-neurology panel, which is based on theinternational MAGNIMS recommendations, is published. The recommendationsinclude a basic and extended diagnostic protocol, an activity monitoringprotocol and a safety protocol. As part of the standardisation, frequencies ofMRI examinations are proposed, and the necessary information for their timingis specified. Implementing this consensus will not only improve the care of MSpatients but also improve the monitoring of MRI parameters within the nationalregistry of MS patients and facilitate negotiations with healthcare providers.

Keywords: multiple sclerosis, magnetic resonance imaging, recommendations, monitoringprotocol, diagnostic protocol, safety, standardised report, prognostic markers

Published: June 1, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vaněčková M, Šťastná D, Ryška P, Tupý R, Keřkovský M, Holešta M, et al.. Standardisation of MRI usage in. Ces radiol. 2024;78(2):101-114. doi: 10.55095/CesRadiol2024/014.
Download citation

References

  1. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17(2): 162-173. doi:10.1016/S1474-4422(17)30470-2 Go to original source... Go to PubMed...
  2. He A, Merkel B, Brown JWL, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020; 19(4): 307-316. doi:10.1016/S1474-4422(20)30067-3 Go to original source... Go to PubMed...
  3. Prosperini L, Mancinelli CR, Solaro CM, et al. Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study. Neurotherapeutics. 2020; 17(3): 994-1004. doi:10.1007/S13311-020-00847-0 Go to original source... Go to PubMed...
  4. Harding K, Williams O, Willis M, et al. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis. JAMA Neurol. 2019; 76(5): 536-541. doi:10.1001/JAMANEUROL.2018.4905 Go to original source... Go to PubMed...
  5. Uher T, Krasensky J, Malpas C, et al. Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis. Neurology(R) neuroimmunology & neuroinflammation 2021; 8(3). doi:10.1212/NXI.0000000000000979 Go to original source... Go to PubMed...
  6. Brown JWL, Coles A, Horakova D, et al. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA 2019; 321(2): 175-187. doi:10.1001/JAMA.2018.20588 Go to original source... Go to PubMed...
  7. Hrnciarova T, Drahota J, Spelman T, et al. Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries. Mult Scler Relat Disord. 2023; 76. doi:10.1016/J.MSARD.2023.104803 Go to original source... Go to PubMed...
  8. Spelman T, Magyari M, Piehl F, et al. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies. JAMA Neurol. 2021; 78(10): 1197-1204. doi:10.1001/JAMANEUROL.2021.2738 Go to original source... Go to PubMed...
  9. Šťastná D, Seňavová J, Andělová M. Interní komorbidity a komplikace terapie roztroušené sklerózy - nenechte se zaskočit! Vnitř. Lék. 2023; 69(5): 294-298. doi:10.36290/vnl.2023.058 Go to original source... Go to PubMed...
  10. Cortese R, Giorgio A, Severa G, De Stefano N. MRI Prognostic Factors in Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Antibody Disease. Front Neurol. 2021; 12. doi:10.3389/FNEUR.2021.679881 Go to original source... Go to PubMed...
  11. Tintore M, Rovira À, Río J, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 2015; 138(Pt 7): 1863- 1874. doi:10.1093/BRAIN/AWV105 Go to original source... Go to PubMed...
  12. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008 Go to original source... Go to PubMed...
  13. (3): 808-817. doi:10.1093/BRAIN/AWM329
  14. Tintore M, Rovira A, Arrambide G, et al. Brainstem lesions in clinically isolated syndromes. Neurology 2010; 75(21): 1933-1938. doi:10.1212/WNL.0B013E-3181FEB26F Go to original source... Go to PubMed...
  15. Preziosa P, Rocca MA, Mesaros S, et al. Relationship between damage to the cerebellar peduncles and clinical disability in multiple sclerosis. Radiology 2014; 271(3): 822-830. doi:10.1148/RADIOL.13132142 Go to original source... Go to PubMed...
  16. Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: progress and challenges. Lancet 2017; 389(10076): 1336-1346. doi:10.1016/S0140-6736(16)30959-X Go to original source... Go to PubMed...
  17. Swanton JK, Fernando KT, Dalton CM, et al. Early MRI in optic neuritis: the risk for disability. Neurology 2009; 72(6): 542-550. doi:10.1212/01.WNL.0000341935.41852.82 Go to original source... Go to PubMed...
  18. Rush CA, Maclean HJ, Freedman MS. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol. 2015; 11(7): 379-389. doi:10.1038/NRNEUROL.2015.85 Go to original source... Go to PubMed...
  19. Calabrese M, Poretto V, Favaretto A, et al. Cortical lesion load associates with progression of disability in multiple sclerosis. Brain 2012; 135(Pt 10): 2952- 2961. doi:10.1093/BRAIN/AWS246 Go to original source... Go to PubMed...
  20. Kubala Havrdová E, Nytrová P. Klinický doporučený postup pro diagnostiku a léčbu roztroušené sklerózy a neuromyelitis optica a onemocnění jejího širšího spektra 2023.
  21. Uher T, Havrdova E, Sobisek L, et al. Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up? Mult Scler. 2017; 23(2): 242-252. doi:10.1177/1352458516650525 Go to original source... Go to PubMed...
  22. Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018; 24(2): 96-120. doi:10.1177/1352458517751049 Go to original source... Go to PubMed...
  23. Tsantes E, Curti E, Collura F, Bazzurri V, Fiore A, Granella F. Fiveand seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month delayed NEDA) in relapsing-remitting multiple sclerosis. J Neurol Sci. 2020; 414. doi:10.1016/J.JNS.2020.116827 Go to original source... Go to PubMed...
  24. Giovannoni G, Popescu V, Wuerfel J, et al. Smouldering multiple sclerosis: the "real MS." Ther Adv Neurol Disord. 2022; 15. doi:10.1177/17562864211066751 Go to original source... Go to PubMed...
  25. Macaron G, Ontaneda D. Diagnosis and Management of Progressive Multiple Sclerosis. Biomedicines 2019; 7(3). doi:10.3390/BIOMEDICINES7030056 Go to original source... Go to PubMed...
  26. Tur C, Carbonell-Mirabent P, Cobo-Calvo Á, et al. Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis. JAMA Neurol. 2023; 80(2): 151-160. doi:10.1001/JAMANEUROL.2022.4655 Go to original source... Go to PubMed...
  27. Šťastná D, Menkyová I, Horáková D. Progresivní roztroušená skleróza ve světle nejnovějších poznatků. Cesk Slov Neurol N. 2023; 86/119(1): 10-17. doi: 10.48095/cccsnn202310
  28. Elliott C, Rudko DA, Arnold DL, et al. Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis. Multiple Sclerosis Journal 2023; 29(6): 680-690. doi:10.1177/13524585231162262/ASSET/IMAGES/LARGE/10.1177_13524585231162262-FIG3. JPEG Go to original source... Go to PubMed...
  29. Pandit L. No Evidence of Disease Activity (NEDA) in Multiple Sclerosis - Shifting the Goal Posts. Ann Indian Acad Neurol. 2019; 22(3): 261-263. doi:10.4103/AIAN.AIAN_159_19 Go to original source... Go to PubMed...
  30. Contentti EC, Correale J. Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis. Drug Des Devel Ther. 2022; 16: 3473-3490. doi:10.2147/DDDT.S348129 Go to original source... Go to PubMed...
  31. Kaul M, End P, Cabanski M, et al. Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clin Transl Sci. 2021; 14(5): 1756-1768. doi:10.1111/CTS.13005 Go to original source... Go to PubMed...
  32. Dolgin E. BTK blockers make headway in multiple sclerosis. Nat Biotechnol. 2021; 39(1): 3-5. doi:10.1038/S41587-020-00790-7 Go to original source... Go to PubMed...
  33. Bhargava P, Kim S, Reyes AA, et al. Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition. Brain 2021; 144(5): 1396-1408. doi:10.1093/BRAIN/AWAB045 Go to original source... Go to PubMed...
  34. Krämer J, Bar-Or A, Turner TJ, Wiendl H. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat Rev Neurol. 2023; 19(5): 289-304. doi:10.1038/S41582-023-00800-7 Go to original source... Go to PubMed...
  35. Montalban X, Arnold DL, Weber MS, et al. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. NEJM 2019; 380(25): 2406-2417. doi:10.1056/NEJMOA1901981/SUPPL_FILE/NEJMOA1901981_DATA-SHARING.PDF Go to original source... Go to PubMed...
  36. Reich DS, Arnold DL, Vermersch P, et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021; 20(9): 729-738. doi:10.1016/S1474-4422(21)00237-4 Go to original source... Go to PubMed...
  37. Stastna D, Drahota J, Lauer M, et al. The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 2021. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. [Ahead of print]. doi:10.5507/BP.2023.015 Go to original source... Go to PubMed...
  38. Vaněčková M, Horáková D, Stastna D, et al. Standardizace využití MR v managementu roztroušené sklerózy. Konsenzus českého expertního radiologicko- -neurologického panelu. Cesk Slov Neurol N. 2024; 87/120(1): 69-77. doi:10.48095/cccsnn202469 Go to original source...
  39. Wattjes MP, Ciccarelli O, Reich DS, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021; 20(8): 653-670. doi:10.1016/S1474-4422(21)00095-8 Go to original source... Go to PubMed...
  40. Vaněčková M, Adámek D, Horáková D. Vyšetřovací MR protokoly pro diagnostiku a monitoraci aktivity u onemocnění roztroušené sklerózy. Neurol Praxi 2022; 23(Suppl CH): 3-14.
  41. Vaněčková M, Horáková D. Současná doporučení pro využití MR u onemocnění roztroušené sklerózy v klinické praxi Neurol Praxi 2023; 24(4): 300-308. Go to original source...
  42. Eisele P, Szabo K, Griebe M, et al. Reduced diffusion in a subset of acute MS lesions: a serial multiparametric MRI study. AJNR Am J Neuroradiol. 2012; 33(7): 1369-1373. doi:10.3174/AJNR.A2975 Go to original source... Go to PubMed...
  43. Maggi P, Absinta M, Grammatico M, et al. Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies. Ann Neurol. 2018; 83(2): 283-294. doi:10.1002/ANA.25146 Go to original source... Go to PubMed...
  44. Clarke MA, Samaraweera APR, Falah Y, et al. Single Test to ARrive at Multiple Sclerosis (STAR-MS) diagnosis: A prospective pilot study assessing the accuracy of the central vein sign in predicting multiple sclerosis in cases of diagnostic uncertainty. Mult Scler. 2020; 26(4): 433-441. doi:10.1177/1352458519882282 Go to original source... Go to PubMed...
  45. Sinnecker T, Clarke MA, Meier D, et al. Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. JAMA Neurol. 2019; 76(12): 1446-1456. doi:10.1001/JAMANEUROL.2019.2478 Go to original source... Go to PubMed...
  46. Mistry N, Dixon J, Tallantyre E, et al. Central Veins in Brain Lesions Visualized With High-Field Magnetic Resonance Imaging: A Pathologically Specific Diagnostic Biomarker for Inflammatory Demyelination in the Brain. JAMA Neurol. 2013; 70(5): 623-628. doi:10.1001/JAMANEUROL.2013.1405 Go to original source... Go to PubMed...
  47. Maggi P, Sati P, Nair G, et al. Paramagnetic Rim Lesions are Specific to Multiple Sclerosis: An International Multicenter 3T MRI Study. Ann Neurol. 2020; 88(5): 1034-1042. doi:10.1002/ANA.25877 Go to original source... Go to PubMed...
  48. Harrison DM, Li X, Liu H, et al. Lesion Heterogeneity on High-Field Susceptibility MRI Is Associated with Multiple Sclerosis Severity. AJNR Am J Neuroradiol. 2016; 37(8): 1447. doi:10.3174/AJNR.A4726 Go to original source... Go to PubMed...
  49. Absinta M, Sati P, Masuzzo F, et al. Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo. JAMA Neurol. 2019; 76(12): 1474-1483. doi:10.1001/JAMANEUROL.2019.2399 Go to original source... Go to PubMed...
  50. Absinta M, Sati P, Schindler M, et al. Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions. J Clin Invest. 2016; 126(7): 2597-2609. doi:10.1172/JCI86198 Go to original source... Go to PubMed...
  51. Suthiphosuwan S, Sati P, Guenette M, et al. The Central Vein Sign in Radiologically Isolated Syndrome. AJNR Am J Neuroradiol. 2019; 40(5): 776-783. doi:10.3174/AJNR.A6045 Go to original source... Go to PubMed...
  52. Uher T, Adzima A, Srpova B, et al. Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences. Mult Scler. 2023; 29(11-12): 1437- 1451. doi: 10.1177/13524585231197076 Go to original source... Go to PubMed...
  53. Tomassini V, Sinclair A, Sawlani V, et al. Diagnosis and management of multiple sclerosis: MRI in clinical practice. J Neurol. 2020; 267(10): 2917-2925. doi:10.1007/S00415-020-09930-0 Go to original source... Go to PubMed...
  54. Toorop AA, van Lierop ZYG, Strijbis E, et al. Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab. Neurol Neuroimmunol Neuroinflamm. 2020; 8(1): e904. doi:10.1212/NXI.0000000000000904. Go to original source... Go to PubMed...
  55. ESUR GUIDELINES ON CONTRAST AGENTS | esur.org. Accessed November 26, 2023. https://www.esur.org/esur-guidelines-on-contrast-agents/
  56. Alessandrino F, Pichiecchio A, Mallucci G, et al. Do MRI Structured Reports for Multiple Sclerosis Contain Adequate Information for Clinical Decision Making? AJR Am J Roentgenol. 2018; 210(1): 24-29. doi:10.2214/AJR.17.18451 Go to original source... Go to PubMed...
  57. Eichinger P, Schön S, Pongratz V, et al. Accuracy of Unenhanced MRI in the Detection of New Brain Lesions in Multiple Sclerosis. Radiology 2019; 291(2): 429-435. doi:10.1148/radiol.2019181568 Go to original source... Go to PubMed...
  58. Lee JK, Bermel R, Bullen J, Ruggieri P, Jones SE. Structured Reporting in Multiple Sclerosis Reduces Interpretation Time. Acad Radiol. 2021; 28(12): 1733- 1738. doi:10.1016/J.ACRA.2020.08.006 Go to original source... Go to PubMed...
  59. Eichinger P, Schön S, Pongratz V, Wiestler H, Zhang H, Bussas M, Hoshi MM, Kirschke J, Berthele A, Zimmer C, Hemmer B, Mühlau M, Wiestler B. Accuracy of Unenhanced MRI in the Detection of New Brain Lesions in Multiple Sclerosis. Radiology 2019; 291(2): 429-435. Go to original source... Go to PubMed...
  60. Vaneckova M, Piredda GF, Andelova M, et al. Periventricular gradient of T1 tissue alterations in multiple sclerosis. Neuroimage Clin. 2022; 34: 103009. doi:10.1016/j.nicl.2022.103009. Go to original source... Go to PubMed...

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.